Related Experiment Video
Updated: Jul 7, 2026
Measuring Naturally Acquired Phagocytosis-Inducing Antibodies to Plasmodium falciparum Parasites by a Flow Cytometry-Based Assay
Published on: August 6, 2020
Apical membrane antigen 1: a malaria vaccine candidate in review
Edmond J Remarque1, Bart W Faber, Clemens H M Kocken
1Department of Parasitology, Biomedical Primate Research Centre, 2280 GH Rijswijk, The Netherlands.
Abstract:
Apical membrane antigen 1 (AMA1) is a micronemal protein of apicomplexan parasites that appears to be essential during the invasion of host cells. Immune responses to Plasmodium AMA1 can have profound parasite-inhibitory effects, both as measured in vitro and in animal challenge models, suggesting AMA1 as a potential vaccine component. However, AMA1 is polymorphic, probably as a result of immune selection operating on an important target of naturally occurring immunity. The current understanding of AMA1 will be presented, particularly in relation to the vaccine potential of AMA1 and the approaches being taken towards clinical development.
Insights
Apical membrane antigen 1 (AMA1) is crucial for apicomplexan parasite invasion. Immune responses targeting AMA1 show parasite inhibition, highlighting its vaccine potential despite polymorphic challenges.
Area of Science:
- Parasitology
- Immunology
- Vaccine Development
Background:
- Apical membrane antigen 1 (AMA1) is a key micronemal protein in apicomplexan parasites.
- AMA1 plays an essential role in the host cell invasion process.
Purpose of the Study:
- To review the current understanding of AMA1.
- To discuss AMA1's potential as a vaccine component.
- To outline approaches for AMA1's clinical development.
Main Methods:
- Review of existing literature on AMA1.
- Analysis of immune responses against Plasmodium AMA1.
- Evaluation of in vitro and in vivo parasite inhibition data.
Main Results:
- Immune responses to AMA1 demonstrate significant parasite-inhibitory effects.
- AMA1 is a polymorphic protein, likely due to immune selection.
- Naturally occurring immunity targets AMA1.
Conclusions:
- AMA1 is a promising candidate for vaccine development against apicomplexan parasites.
- Addressing AMA1 polymorphism is critical for successful vaccine design.
- Further research is needed to advance AMA1-based vaccines into clinical trials.
More Related Videos
08:46Myeloid Cell Isolation from Mouse Skin and Draining Lymph Node Following Intradermal Immunization with Live Attenuated Plasmodium Sporozoites
Published on: May 18, 2016
05:28Standard Membrane Feeding Assay for the Detection of Plasmodium falciparum Infection in Anopheles Mosquito Vectors
Published on: May 12, 2022
